Tenaya Therapeutics, Inc. (TNYA) Morgan Stanley twenty third Annual World Healthcare Transcript

Michael Ulz
Fairness Analyst

Okay. Nice. Good afternoon, everybody, and thanks for becoming a member of us on the Morgan Stanley World Healthcare Convention. I am Michael Ulz, one of many biotech analysts right here. And it is my pleasure to introduce Faraz Ali, CEO of Tenaya Therapeutics. Earlier than we get began, I simply have to learn a fast disclosure. For essential disclosures, please see the Morgan Stanley analysis disclosure web site at www.morganstanley.com/researchdisclosures. And in case you have any questions, please attain out to your Morgan Stanley gross sales consultant. And with that, Faraz, thanks for becoming a member of us at the moment, and I am going to — perhaps I am going to hand it over to you, and you may give us some simply introductory feedback for those who is probably not acquainted…

Faraz Ali
CEO, Interim Principal Monetary Officer & Director

Sure. Simply total, earlier than we dive into the deeper questions, I simply wished to say that we have had a terrific begin to the 12 months and searching ahead to closing sturdy. All the pieces that we set out do in our steering, we have achieved. So on our 201 lead gene remedy program for the main genetic explanation for HCM, we dosed — efficiently dosed the high-dose cohort, efficiently obtained the DSMB clearance, which is essential from a security perspective. We have launched information from our pure historical past research, which is the biggest pure historical past research on this planet for this illness for the kids with this mutation, a really extreme illness.

After which we’re on monitor to ship information within the second half of this 12 months, and we had first narrowed our steering to This autumn, however we’re joyful to